Antiva Biosciences, Inc. announced that it expects to receive $31.662809 million in funding
October 21, 2021
Share
Antiva Biosciences, Inc. announced that it will issue 56,784,090 series D preferred shares at an issue price of $0.5576 per share for the gross proceeds of $31,662,808.584 on October 22, 2021. The shares are convertible, participating, non-redeemable and non-cumulative. The shares carry non-cumulative fixed dividend value of $0.045 per annum per share.
The shares will be convertible in common shares at a fixed conversion price of $0.5576 per share. The company will issue securities pursuant to exemption provided under Regulation D.
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.